Introduction
Invasive pulmonary aspergillosis (IPA) has emerged as an important cause of morbidity and mortality in patients and 100% [13 -16] . For these patients with COPD, the results of a single GM determination and isolation of Aspergillus from respiratory tract samples may be helpful in the diagnosis of IPA [8, 10, 17] . However, the value of serial GM determinations for critically ill COPD patients is unknown.
Isolation of Aspergillus from samples of critically ill patients is indicative of a poor prognosis and is associated with high mortality, irrespective of invasion or colonization [18, 19] . GM can serve as a surrogate endpoint for IPA outcomes in neutropenic hematology patients [20] . The value of consecutive serum GM assays relative to IPA for critically ill COPD patients is unclear.
The aim of this prospective, single center cohort study was to assess the diagnostic and prognostic values of two consecutive serum GM determinations for IPA in critically ill COPD patients admitted to an ICU.
Patients and methods

Study population and data collection
The study was conducted in the respiratory intensive care unit (RICU) of Beijing Chao-Yang Hospital, a teaching facility of the Capital Medical University in Beijing, China. Critically ill stage III or IV COPD (Global Initiative for Chronic Obstructive Lung Disease; GOLD) patients who were admitted to the ICU between February 2007 and November 2009, were included in the study [8, 10] . This investigation had the approval of the Ethics Committee of Beijing Chao-Yang Hospital and informed consent was obtained from all study subjects or their next of kin.
Case defi nitions of IPA
Patients were included in our study on the fi rst day of their ICU admissions. Each patient was classifi ed as having 
Serum GM detection
It has been suggested that serum GM should be tested at least twice a week to achieve early diagnosis of aspergillosis [8] . Consecutive serum samples for GM studies were collected on the fi rst and the fourth days of the patient ' s admission to the ICU. A sandwich ELISA assay for GM detection (Platelia Aspergillus ; Sanofi Diagnostics Pasteur, Marnes-La-Coquette, France) was used according to the manufacturer ' s instructions. An optical density (OD) ratio of 0.5 or greater was considered positive.
Statistical analysis
Patients were classifi ed as having or not having IPA. Using this standard, the ability to predict infection in critically ill COPD patients on the basis of GM were assessed with respect to; (i) the fi rst test being positive, (ii) the second test being positive, (iii) at least one of the two consecutive GM tests being positive, and (4) positive outcomes for both GM tests. The sensitivity, specifi city, positive predictive value, and negative predictive value of the test, along with 95% confi dence intervals (95% CI), were calculated for each determination strategy. Receiver operating characteristic (ROC) curves were constructed to compare differences in performance of a positive GM determination of a fi rst sample and at least one positive of the two consecutive GM determinations. The mortalities of patients during their ICU admissions for different groups and for different diagnostic strategies were compared using Fisher ' s exact test. P values less than 0.05 were considered signifi cant. The statistical analysis used SPSS version 11.5.
Results
Patient characteristics
During the study period, 653 patients were admitted to our RICU, of whom 171 had COPD. Of these, 90 critically ill COPD (GOLD III or IV) patients were included in this study. Aspergillus spp. were isolated from the respiratory tract samples of 20 of these patients. According to the diagnostic criteria for IPA, one had proven and 18 probable invasive aspergillosis (Table 1 ). Of the 19 IPA patients, 11 cases were admitted directly to the ICU from the emergency department, and 8 patients were transferred from the respiratory medicine ward to the ICU after a median ward stay of 5 days (range 1 -18 days). The incidence of IPA in the COPD patients admitted to the ICU was 11.1% (19/171). Fifteen episodes were caused by Aspergillus fumigatus , A. fl avus was the etiologic agent in three patients and A. versicolor was isolated along with A. fumigatus from one patient. In the other four patients, A. fl avus was isolated from one, A. versicolor was recovered from another, and A. niger was found in cultures of samples from two patients.
All episodes had a pulmonary clinical presentation, i.e., halo sign, air-crescent sign, or cavity within an area of consolidation on CT scan or symptoms of LRT infection, pleural rub, new infi ltrate without an alternative diagnosis. All the 19 IPA patients had infi ltrates on their chest radiographs. Seven patients had chest CT scans in which nodules, patching and consolidation were found, cavities were noted in two cases, but no halo signs were found in any cases ( Table 1 ).
The mortality rates for the entire study population, the IPA group and the non-IPA group were 33.3% (30/90), 73.7% (14/19), and 22.5% (16/71), respectively. The mortality of patients who had Aspergillus isolated from the respiratory tract was 70.0% (14/20). The mortality rate of the IPA group was signifi cantly higher than those of the entire study population and the non-IPA group ( P ϭ 0.002 and P Ͻ 0.001, respectively).
Lung biopsy was performed for one case, and no autopsies were performed for this study.
Diagnostic values of single and two consecutive GM Tests
All 90 of the critically ill COPD patients received their fi rst GM tests when they were admitted to the RICU, and 69 patients who were in the ICU for more than 4 days received a second GM test on the fourth day of their ICU stay. Of the 21 patients from whom a second sample was not obtained due to being released from the ICU in less than 4 days, 10 died and 11 refused to submit to GM tests once transferred to a general ward. Seventeen of 19 IPA patients had two consecutive GM tests.
A total of 159 serum GM tests were conducted on samples from all patients. The OD ratio had a minimum value of 0.126 and a maximum value of 4.553. For positive results, the average OD ratio was 1.234 (median ϭ 0.867; range: 0.652 -1.432).
Using a cut-off of 0.5 ng/ml, the fi rst and the second GM tests of the entire study population, yielded positive values in 20 and 17 patients, respectively. Twenty-two patients had at least one positive GM result out of the two consecutive tests, while both tests were positive for 11 patients.
Eleven of the 19 IPA patients were positive on the fi rst GM tests, 11 had positive results on the second assay, 12 patients had at least one positive GM result in the two consecutive tests, and only eight patients were positive in both GM tests. Three cases that were positive on the second test were initially negative. Both of the GM tests were positive for the patient with proven IPA (Table 1) , but both tests were negative for those with Aspergillus colonization.
The performance characteristics of positive GM results in the fi rst tests as compared with at least one positive GM result on two consecutive tests were assessed using ROC curve analysis (Fig. 1) . The sensitivities, specifi cities, positive and negative predictive values, and total consistent rates for positive GM results on the fi rst test, on the second test, on at least one positive GM result of the two consecutive tests, and two consecutive GM tests are shown in Table 2 . The total consistent rates did not show signifi cant differences between different diagnostic strategies.
Before or during their ICU stay, 9 of 90 patients were treated with piperacillin -tazobactam, and both consecutive GM tests were positive for one of these 9 patients. The GM results for the other eight patients were all negative. No patients were treated with amoxicillin -clavulanate.
Of the 19 patients with IPA, two were receiving broadspectrum antifungal agents when GM sampling was done. While both of the consecutive GM tests were negative for one of these two patients, Aspergillus was isolated from the respiratory tract sample of this individual (Table 1 , case 47).
For the three non-IPA patients with two positive GM results, only one received piperacillin -tazobactam treatment and one received low dose steroid treatment before and during their ICU stay. Although consolidation was found on the chest X-ray of one of the patients, none was found with the other two patients. Candida albicans was cultured from a LRT sample of one patient, who then received fl uconazole. None of these three patients received anti-Aspergillus therapy and all survived.
The prognostic value of GM
The mortality rates of patients during their ICU stays who had positive GM results on the fi rst test, at least one positive of the two consecutive tests, and positive results for both consecutive tests were, respectively, (a) 60% (12/20), 54.6% (12/22), and 72.7% (8/11) for all patients, (b) 81.8% (9/11), 83.3% (10/12), and 72.7% (8/11) for IPA patients, and (c) 33.3% (3/9), 20% (2/10), and 33.3% (1/3) for non-IPA patients. Using the strategy of at least one positive of two consecutive tests, the IPA group had a signifi cantly higher mortality rate (83.3% vs. 20%, P ϭ 0.003) when compared with the non-IPA group patients. Different diagnostic strategies did not make a signifi cant difference in mortality of IPA and non-IPA patients. There were no signifi cant differences in mortality between patients with increasing GM levels (i.e., fi rst result negative, while second positive) and those with decreasing GM levels over time (i.e., fi rst result positive, while second negative). 6 (73.7 -91.6) Abbreviations: COPD ϭ chronic obstructive pulmonary disease; PPV ϭ positive predictive value; NPV ϭ negative predictive value; TCR ϭ total consistent rate.
Discussion
COPD patients, especially those that are critically ill and require admission to an ICU, are increasingly recognized as an emerging population at risk for opportunistic invasive pulmonary aspergillosis [10, 12, 13] . COPD patients frequently experience acute exacerbations of their underlying illness, and IPA may be a possible cause of these acute respiratory incidents. Diagnosis of IPA in COPD remains diffi cult because its signs and symptoms are non-specifi c and may be masked by steroid treatment. These patients have a very high mortality rate, in spite of suffi cient support and antifungal treatment. Therefore, early diagnosis seems crucial for improving their prognosis [8] .
Evaluations of the value of GM assays in the diagnosis of IPA in COPD patients are limited. Previous studies showed that a single GM assay had a sensitivity of only 44 -60% for patients with proven or probable IPA [4, 13, 17] . It has been hypothesized that neutrophils are capable of clearing GM from the blood by mannose-binding receptors on the cells ' surfaces [22] . Since COPD patients are not neutropenic, the clearance of GM might explain the low sensitivity of serum GM tests in the diagnosis of IPA.
It may not be necessary or economically feasible to do serial GM tests for all hospitalized COPD patients. However, for those that require ICU admission, it is reasonable to do consecutive GM tests since they are at high risk of IPA. In our study, three IPA patients for whom the GM tests were initially negative, were found to be GM positive on repeat testing. This may have been the result of an increasing fungal burden, which may have, in turn, impacted on the sensitivity of GM tests in this population [23 -25] .
In addition, the value of consecutive determinations has not been evaluated. In the criteria proposed by Bulpa et al . [8] , two consecutive positive serum GM tests were suggested as a microbiological diagnostic criterion. In addition, a study by Guinea et al . [17] , demonstrated that a single GM test had sensitivities of only 60% and 40% when using a cut-off of 0.5 and 1.0, respectively. However, our investigation indicated that using the criterion of at least one positive GM result of two consecutive tests in the diagnosis of IPA in critically ill COPD patients may have a relatively high sensitivity of 70.6%, with a comparable total consistent rate of 78.2% in comparison to the other three diagnostic strategies. Moreover, we noted that two consecutive positive GM results had the highest specifi city of 94.2%, but a relatively low sensitivity of 47.1%.
Further, several studies have suggested that isolation of Aspergillus from critically ill patients was a marker of a poor prognosis and was associated with high mortality, irrespective of invasion or colonization [18] . The mortality rates were 50% for those patients colonized by this fungus and 80% for those with invasive disease [19] . A recent study of neutropenic hematology patients indicated that serum GM detection was strongly correlated with survival, autopsy fi ndings, and response outcomes [20] . Our investigation indicated that the mortality rate for critically ill COPD patients with positive serum GM results was as high as 54.6 -72.7%. It was even higher, i.e., from 72.7 -83.3%, when Aspergillus was isolated from the respiratory tract samples in association with single or consecutive positive GM results. Therefore, a positive GM result, particularly when combined with the isolation of Aspergillus , may indicate a poor outcome.
In previous reports, IPA affected 1.63 -1.91% of hospitalized COPD patients [10, 26] . The incidence of IPA in this patient population from whom the fungus was recovered in culture was 16.1 -22.1% [10, 17] . This incidence was even higher at 37% for those COPD patients whose specimens yielded Aspergillus and who required admission to the ICU [10] . In this study, the incidence of IPA in the COPD patients admitted to the RICU was 11.1%, which was similar to previous studies.
One limitation of our study was that only one case was diagnosed as proven IPA. Futhermore, the false positive and false negative rates of GM detection for the study population could not be statistically evaluated.
Conclusion
At least one positive result of two consecutive serum GM tests appears to be useful in the diagnosis of IPA in critically ill COPD patients admitted to an ICU. In addition, positive serum GM results combined with the recovery of Aspergillus from respiratory samples may be a potential marker of high mortality. The value of this approach needs to be confi rmed in future trials.
